News Sobi's long-serving CEO Guido Oelkers to step down After nearly a decade in the role, Guido Oelkers is stepping down as chief executive of Sobi to take the top job at BioNTech.
News Are we about to see a return for the pharma mega-merger? There are rumours that the first pharma 'mega-merger' for several years – between AstraZeneca and Bristol Myers Squibb – is under discussion.
News ZEUS delivers a bolt of pain to Novo Nordisk Novo Nordisk's IL-6 inhibitor ziltivekimab has failed the phase 3 ZEUS trial in heart disease, denting its bid to expand into new therapeutic areas.
News Apnimed IPO raises $192m, as three other biotechs set terms Sleep apnoea drug developer Apnimed has completed its IPO, raising $192m, while Braveheart, Attovia, and Vogenx reveal their terms.
News Pfizer cues up vitiligo filing for Litfulo after phase 3 win Pfizer's JAK inhibitor Litfulo hits the mark in vitiligo, setting up filings, as Incyte claims EU approval for Opzelura in atopic dermatitis.
News Sanofi drops two more programmes in R&D clear-out Shortly after terminating one late-stage R&D programme, Sanofi confirmed in its second-quarter update that two others are being scrapped.
News Enhertu OK ends 10-year EU gap in frontline breast cancer Enhertu plus Perjeta has become the first new frontline therapy approved for advanced HER2-positive breast cancer in the EU for over a decade.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
